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Although syndromic surveillance systems using non-
clinical data have been implemented in the United States,
the approach has yet to be tested in France. We present
the results of the first model based on drug sales that
detects the onset of influenza season and forecasts its
trend. Using weekly lagged sales of a selected set of med-
ications, we forecast influenzalike illness (ILI) incidence at
the national and regional level for 3 epidemic seasons
(2000-01, 2001-02, and 2002-03) and validate the model
with real-time updating on the fourth (2003-04). For nation-
al forecasts 1–3 weeks ahead, the correlation between
observed ILI incidence and forecast was 0.85–0.96, an
improvement over the current surveillance method in
France. Our findings indicate that drug sales are a useful
additional tool to syndromic surveillance, a complementary
and independent source of information, and a potential
improvement for early warning systems for both epidemic
and pandemic planning.
D
isease surveillance provides essential information for
control and response planning. It helps identify
changes in incidence and affected groups, thereby provid-
ing valuable additional time for public health interven-
tions. Syndromic surveillance aims to use health and
health-related data that precede diagnosis or confirmation
to identify possible outbreaks, mobilize a rapid response,
and thus reduce illness and deaths. This approach is
increasingly being explored by public health officials to
detect any emerging event (e.g., bioterrorist attacks) and
for routine surveillance (1–6).
In France, an existing Web-based surveillance system
that uses a syndromic approach by collecting weekly office
visits to general practitioners provides forecasts of influen-
za. This approach, based on the method of analogs, pro-
duces reasonably sensitive forecasts of annual influenza
epidemics (interpandemic influenza) (7). However, the
method uses past observed patterns of influenzalike-illness
(ILI) to forecast future incidence of influenza and may not
be able to detect new or unusual public health events, such
as the emergence of a pandemic strain of influenza or a
bioterrorist attack. For this reason, we investigated other
potential data sources associated with ILI that do not rely
on past information to forecast incidence and are flexible
enough to detect unusual increases in incidence. Here, we
evaluate the potential benefit of using a complementary
and independent dataset to forecast ILI and eventually to
detect influenza epidemics in France. We also compare 2
surveillance methods that use a syndromic approach (one
that monitors syndromes defined in clinical terms [ILI] and
the other that concerns syndromes defined by using a con-
stellation of drug-specific pharmacy sales indicators).
Drug sales have the advantages of providing data on wide-
ly used products and of being available in real time.
Purchases of drugs could be rapidly relayed to public
health authorities, potentially providing lead time for epi-
demic response planning (8). 
Materials and Methods
Drug Sales
We used 2 data sources aggregated at the national and
regional level. The first database consists of most weekly
prescription and over-the-counter (OTC) drug sales, from
July 1, 2000, to August 22, 2004, provided by IMS France
(http://www.imshealth.com). These data are available in
quasi–real time; 7–10 days of lag time are needed for
Medication Sales and Syndromic
Surveillance, France 
Elisabeta Vergu,*†‡1 Rebecca F. Grais,*†1 Hélène Sarter,*† Jean-Paul Fagot,*† Bruno Lambert,§
Alain-Jacques Valleron,*†¶ and Antoine Flahault*†#
RESEARCH
416 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 12, No. 3, March 2006
*Institut National de la Santé et de la Recherche Medicale Unité,
Paris, France; †Université Pierre et Marie Curie, Paris, France;
‡Institut National de la Recherche Agronimique MIA, Jouy-en-
Josas, France; §IMS FRANCE, Puteaux, France; ¶Hôpital Saint-
Antoine, Paris, France; and #Hôpital Tenon, Paris, France  1Both authors contributed equally to this research.quality control and consolidation. The database includes
11,000 pharmacies throughout France (≈50% of all phar-
macies) at the regional level (21 regions). The data, con-
sisting of nearly 500 classes of medications, give the
number of units dispensed or sold during a certain week
for each class of drugs, identified by their codes in the
European Pharmaceutical Marketing Research Association
Anatomical Therapeutic Chemical (ATC4) classification.
In this international classification, drugs are identified by a
unique ATC4 code, which corresponds to their primary
use. A panel of experts from the World Health
Organization Collaborating Center selected 19 classes of
medications (Table 1) likely to be prescribed or purchased
for ILI. This preselection also avoids the construction of
saturated models.
For all years (2001–2004), an aberration in the data for
the first week of January was present, likely due to the
New Year’s holiday. We used the preceding and following
weeks to estimate for the week of January 1. Figure 1
shows the temporal trends of sales of 2 of the 19 classes of
medications (cephalosporin and expectorants) used in this
analysis as an example, as well as the concomitant nation-
al ILI incidence. The other classes of drugs included in the
analysis follow similar temporal trends (data available on
request from the authors).
ILI Incidence
Data on ILI incidence were obtained from the French
Sentinel Network (FSN), which comprises voluntary sen-
tinel general practitioners who update a Web-accessible
database with information on communicable diseases
including ILI. Weekly national and regional ongoing ILI
incidence estimates are published on the Web
(http://www.sentiweb.org). ILI is defined by sudden onset
of fever of >39°C, respiratory symptoms, and myalgia.
Epidemic weeks are defined according to a periodic sea-
sonal regression model (based on the concept of excess
deaths—here, excess illness—introduced by Serfling [9])
that is used routinely in FSN (10,11). Epidemic onset is
defined as the first week in which the national ILI inci-
dence exceeds a baseline nonepidemic threshold given by
the upper limit of the 95% confidence interval of the
Serfling model, provided the incidence remains above this
threshold for at least 2 consecutive weeks.
Model Construction
We used a Poisson regression model to forecast inci-
dence of ILI based on medication sales. The model allows
for overdispersion (when the variance may be larger than
the mean in the raw data on ILI incidence and medication
sales). The exponential of the estimated Poisson regression
coefficients indicates the relative influence of each med-
ication on the incidence of ILI in France. For the explana-
tory variables (i.e., drug sales data), various time lags were
tested (from 0 to 4 weeks). To avoid correlation generated
by several lagged values of the same variable (which can
bias estimated variance of calculated coefficients), only 1
lagged version of a given explanatory variable was kept.
We kept only the time-lagged variable (i.e., sales from 0,
1, 2, 3, or 4 weeks lagged) most correlated to ILI inci-
dence.
Variables were introduced in the model by stepwise
selection at the 5% significance level. Sine and cosine
terms were included in the model to control for the annual
seasonality of ILI incidence. Autoregressive terms (i.e.,
past terms of the ILI time series) were included if neces-
sary in the final model to eliminate the autocorrelation of
the residuals, a common problem in time-series data. The
final structure of the model is: 
Observed incidence of ILI [week t] = exp{intercept + coeff ×
observed incidence of ILI [week (t – tILI)] + coeff × sales of
drug A[week (t – tA)] + coeff × sales of drug B [week (t – tB)]
+ … + coeff × sine(2πt / 52) + coeff × cosine(2πt / 52)},
where drug A, drug B, and the like correspond to class-
es of drugs marked by an asterisk in Table 1, coeff denotes
respective coefficients of included variables, and tILI, tA,
tB, and the like represent respective time-lags of these
variables. We constructed 1-, 2- and 3-week-ahead predic-
tive models at national and regional levels on a training
dataset corresponding to the period from July 1, 2000, to
September 14, 2003, when 3 outbreaks occurred. More
details on the predictive models are provided in the online
Appendix (available from http://www.cdc.gov/ncidod/
EID/vol12no03/05-0573_app.htm).
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A jackknife-based resampling procedure (12), which
produces error bounds on the estimate of regression coef-
ficients computed from samples that leave out 1 observa-
tion at a time, was used to check the model fit. The models
were validated by forecasting the 2003–2004 influenza
season (September 15, 2003–August 22, 2004). Models’
parameters were reestimated each week with updated data
on medication sales and ILI incidence. The predictions of
ILI incidence from drug sales were evaluated by Spearman
correlation coefficients. The correlation between observed
and forecasted incidences was assessed for each forecast-
ing horizon (1, 2, and 3 weeks ahead) for the entire
2003–2004 influenza season (September 15, 2003–August
22, 2004) and for the preepidemic and epidemic weeks
(October 6, 2003–January 4, 2004). When regional models
were evaluated, the correlation was calculated as the aver-
age of the 21 regional correlation coefficients.
We compared the results of the proposed method to the
current forecasting approach, the method of analogs, for
the national model. The method of analogs, currently
employed by FSN, uses weighted sums of vectors selected
from historical influenza time series that match current
activity to construct forecasted incidences (7). All statisti-
cal procedures were generated with SAS software, version
8 (SAS Institute, Cary, NC, USA).
Results 
National ILI Incidence Forecast
The fitted predictive models for the training dataset for
1, 2, and 3 weeks ahead included 14 of the 19 preselected
classes of drugs likely to be prescribed or purchased for
ILI (Table 1). The correlation coefficients calculated on the
training dataset between observed and model-recalculated
ILI incidences were 0.94, 0.92, and 0.91 for 1-, 2-, and 3-
week-ahead predictions, respectively (p<0.001, Figure 2).
The validation of these models, evaluated first on the
entire period from September 15, 2003, to August 22,
2004, and secondly on the preepidemic and epidemic
weeks of the 2003–2004 influenza season, provided corre-
lation coefficients of 0.85 to 0.96 (Table 2). The correla-
tion decreased as the time horizon for the forecast
increased. The method detects well the beginning of the
epidemic but overestimates the epidemic size (data not
shown).
The prediction accuracy of our drug sales–based model
at a national level was compared with that of the current
forecasting method (the method of analogs). As illustrated
in Table 2, although the correlation coefficients lie in the
same range of values for both methods, they are generally
higher with our method. 
Regional ILI Incidence Forecast
At the regional level, 5 classes of medications appeared
in at least half of the final selected models (Table 1). These
variables are also the most informative in the national
model (likelihood test).
The prediction accuracy, defined here as the average
correlation coefficient for the 21 regions of France, was
0.54–0.70; it decreased slightly with the forecasting hori-
zon. Compared to the national model, the regional models
performed less well. Our regional predictive models gave
higher correlation values than the method of analogs for
both periods and all forecast horizons except when the ILI
incidence was calculated 1 week in advance (Table 2).
Forecasted versus observed regional ILI incidences were
mapped (Figure 3) for the 6 first weeks of the 2003–2004
influenza epidemic (November 3, 2003–December 14,
2003). Each map of predicted regional ILI incidences was
constructed at 1-, 2-, or 3- week horizons. For example, for
week 49 of 2003, hereafter designated 2003(49), we pro-
vided a 2-week-ahead prediction of ILI incidence, calcu-
lated by employing the model using data until the week
2003(47).
Discussion
Our work presents a real-time approach to detect
influenza outbreaks and predict trends of ILI incidence 1,
2, or 3 weeks ahead with good reliability. Our method,
based on drug sales data, provides similar results as the
method that uses report of visits for ILI from sentinel
physicians.
The set of drug classes proposed for inclusion in the
model was preselected by a panel of experts at the World
Health Organization Collaborating Center, based on what
they determined to be clinically relevant. Because >500
medication classes are included in the database, we select-
ed a smaller number to avoid overparameterization. This a
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Figure 1. Example of weekly consumption of expectorants and
cephalosporins (provided by IMS France) in phase with weekly
incidence of influenzalike illness (ILI) (data from French Sentinel
Network) per 100,000 population. priori selection may have influenced our results, in partic-
ular application of the model at the regional level.
Regional demographic, climatologic, and cultural differ-
ences may influence the types of medication prescribed
and purchased.
After the stepwise procedure for inclusion in the
Poisson regression models, the selected medication groups
were both OTC and prescription medications purchased
and prescribed for varying degrees of severity of ILI symp-
toms or complications of influenza. For example, an OTC
drug such as vitamin C may be purchased before or at the
onset of ILI symptoms since popular beliefs and advertis-
ing suggest it may prevent infection or lessen symptom
severity (13), even in the lack of any evidence or regulato-
ry approval. Cephalosporins, second-line antimicrobial
agents, are often used to treat acute bacterial rhinosinusi-
tis, a complication of ILI symptoms present for an extend-
ed period (14).
At the national level, our forecasting model showed
overall good agreement with the observed data on ILI inci-
dence from the FSN surveillance system (Table 2). Over
time, the correlation coefficients between observed and
forecast ILI time series decreased, although they remained
>0.85. The fact that the model was updated on a weekly
basis contributed to the overall stability of the method’s
accuracy. However, the method does not perform as well
when used as a tool to quantify the overall epidemic
impact (data not shown). Because the main objective of the
method is to provide advance warning for onset of the epi-
demic, this limitation is less important.
At the regional level, the medications included varied
from area to area, but 5 drug therapeutic classes were
selected for all models (Table 1). This variation may be
explained by the fact that while regional similarities exist,
different external factors could influence medication con-
sumption. In terms of the forecast accuracy, the correlation
coefficients averaging over the 21 regions of France were
weaker than those obtained at the national level on the val-
idation dataset (range 0.54–0.70). This may be due to the
method itself, which may perform less efficiently at a
regional level, or to the quality of the observed regional
ILI datasets, since they are obtained from a sample of sen-
tinel physicians. However, the accuracy at the regional
level may be sufficient for operational purposes, since the
qualitative trend is more relevant than the quantitative
evaluation. Using the method at the regional level also pro-
vides an additional means to follow the spatial diffusion of
the epidemic wave on the basis of a robust and powerful
sample of pharmacies distributed all over the country.
We compared our drug sales–based forecasting models
to a nonparametric method routinely used by FSN (method
of analogs) (7). The results obtained appear to be better
than those obtained with the method of analogs, but the
comparison between the 2 methods is only partial: the
method of analogs exploits historical trends to forecast
forthcoming ILI events, whereas the regression analysis
does not (except for the autoregressive term). In the event
of an influenza pandemic or other event not previously
observed, our method would be more likely to predict
trends that have never been seen in the recent interpandem-
ic past than the method of analogs, which uses a 20-year
time series to forecast the future.
As with all forecasting models, the results of this
research highlight changes in trends rather than prediction
of actual incidence. Only 4 epidemic seasons of data were
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Figure 2. Model construction for national influenzalike illness (ILI)
incidence forecasting 1, 2, and 3 weeks ahead for the training
dataset (week 36 of year 2000 to week 38 of year 2003) by using
a jackknife reestimation procedure (95% confidence intervals [CI]
for estimations are given). Forecasted incidence is per 100,000.available to both fit and validate the model. The addition
of years of retrospective data would probably slightly
improve the forecast accuracy at the national level but
might greatly improve precision at the regional level.
Value of Additional ILI Surveillance System 
Our findings confirm previous studies that demonstrate
the utility of using drug sales, and the timing of drug sales,
compared to other indicators (8,15), as a proxy indicator of
ILI activity. Several arguments support the need to consid-
er syndromic surveillance based on drug-sales data. First,
the nonspecific prodrome phase of many diseases may be
self-treated before persons see a health practitioner and
may therefore be more easily detected by using drug sales
than laboratory surveillance or health center discharges.
Second, rapidly extending the use of this method may be
more feasible than creating or expanding sentinel networks
of general practitioners. Drug sales are usually available in
many developed countries, whereas electronic real-time
surveillance of influenza or ILI is still seldom set up in
most parts of the world. Third, using several sources of
data with different methodologic approaches for syn-
dromic surveillance may improve detection and prediction
of trends of ILI outbreaks caused by influenza or other
emerging agents. Drug-sales series represent an independ-
ent source of information, as well as reports from labora-
tories, general practitioners, hospitals, and death
certificates, which have proved their usefulness in moni-
toring and assessing the impact of influenza epidemics. 
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Figure 3. Evolution of regional influenzalike illness (ILI) incidence during the 2003–2004 epidemic. The observed maps (first line) were
constructed by using data from the French Sentinel Network. The forecast maps (for the first 6 epidemic weeks) 1, 2, and 3 weeks ahead
show the results of the regional models when medication sales are used. The forecast horizon is indicated below each map. For exam-
ple, for 2003(49), ILI predicted incidence is calculated by employing the model with data until week 47 of year 2003. Thus, the time fore-
casting horizon is 2 weeks. Accuracy of Drug Sales–based Surveillance System
Methods for assessing the quality of a syndromic sur-
veillance system have been recently proposed by
Buckeridge et al. (16). Our drug-sales time series was too
short to allow a precise assessment of system’s capacity to
detect outbreaks appropriately. Our findings do indicate,
however, that drug sales are good predictors of ILI activi-
ty recorded by the sentinel system. FSN has monitored ILI
activity in France with the same method since 1984. For 21
years, during each winter, an influenza epidemic has been
detected by the 2 French national influenza centers (based
in Lyon and Paris) on the basis of virus isolation and
simultaneously by FSN. Thus, FSN has shown a high sen-
sitivity to detect national influenza epidemics, and we may
assume that the system based on drug sales will be at least
as sensitive as that of FSN. A potential advantage of the
medication sales data is that their broad scope may
enhance the sensitivity of detection, especially at a local
level. This hypothesis has to be further assessed by evalu-
ating a longer time period or by using simulated data for
evaluation. Although using drug sales as a monitoring tool
has clear benefits, detecting a nonspecific signal from our
system would require further confirmation and identifica-
tion of the causes of this unusual increase.
Conclusions
Our results confirm that drug-sales data could be used
as an independent additional source of information to warn
of ILI outbreaks early in countries where influenza is
already monitored. Drugs-sales data may be the only mon-
itoring ILI system in countries without existing surveil-
lance systems. The proposed method has the advantage of
being both practical and relatively simple to implement.
Therefore, this approach could be easily extended to other
infectious diseases. In many industrialized countries, sim-
ilar databases of medication sales are available in real or
near-real time.
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